BCDA
Price
$2.12
Change
+$0.04 (+1.92%)
Updated
Jul 3 closing price
Capitalization
10.98M
INO
Price
$1.33
Change
-$0.81 (-37.85%)
Updated
Jul 3 closing price
Capitalization
48.78M
Interact to see
Advertisement

BCDA vs INO

Header iconBCDA vs INO Comparison
Open Charts BCDA vs INOBanner chart's image
BioCardia
Price$2.12
Change+$0.04 (+1.92%)
Volume$3.04M
Capitalization10.98M
Inovio Pharmaceuticals
Price$1.33
Change-$0.81 (-37.85%)
Volume$21.09M
Capitalization48.78M
BCDA vs INO Comparison Chart in %
Loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCDA vs. INO commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a StrongBuy and INO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (BCDA: $2.12 vs. INO: $1.33)
Brand notoriety: BCDA: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 2144% vs. INO: 1778%
Market capitalization -- BCDA: $10.98M vs. INO: $48.78M
BCDA [@Biotechnology] is valued at $10.98M. INO’s [@Biotechnology] market capitalization is $48.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 5 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).

  • BCDA’s TA Score: 5 bullish, 3 bearish.
  • INO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BCDA is a better buy in the short-term than INO.

Price Growth

BCDA (@Biotechnology) experienced а -4.93% price change this week, while INO (@Biotechnology) price change was -40.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

BCDA is expected to report earnings on May 14, 2025.

INO is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INO($48.8M) has a higher market cap than BCDA($11M). BCDA YTD gains are higher at: -2.752 vs. INO (-25.281). BCDA has higher annual earnings (EBITDA): -8.39M vs. INO (-93.37M). INO has more cash in the bank: 68.4M vs. BCDA (949K). BCDA has less debt than INO: BCDA (850K) vs INO (11.3M). INO has higher revenues than BCDA: INO (283K) vs BCDA (3K).
BCDAINOBCDA / INO
Capitalization11M48.8M23%
EBITDA-8.39M-93.37M9%
Gain YTD-2.752-25.28111%
P/E RatioN/AN/A-
Revenue3K283K1%
Total Cash949K68.4M1%
Total Debt850K11.3M8%
FUNDAMENTALS RATINGS
BCDA vs INO: Fundamental Ratings
BCDA
INO
OUTLOOK RATING
1..100
872
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
8056
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (48) in the Medical Specialties industry is somewhat better than the same rating for BCDA (90) in the null industry. This means that INO’s stock grew somewhat faster than BCDA’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BCDA (100) in the null industry. This means that INO’s stock grew similarly to BCDA’s over the last 12 months.

INO's SMR Rating (98) in the Medical Specialties industry is in the same range as BCDA (100) in the null industry. This means that INO’s stock grew similarly to BCDA’s over the last 12 months.

INO's Price Growth Rating (56) in the Medical Specialties industry is in the same range as BCDA (80) in the null industry. This means that INO’s stock grew similarly to BCDA’s over the last 12 months.

INO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as BCDA (100) in the null industry. This means that INO’s stock grew similarly to BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDAINO
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XOMA26.960.85
+3.26%
XOMA Royalty Corporation
APYX2.290.05
+2.23%
Apyx Medical Corp
GOOG180.550.79
+0.44%
Alphabet
GTY27.95N/A
N/A
Getty Realty Corp
IONS43.00-0.59
-1.35%
Ionis Pharmaceuticals

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with RPTX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-37.85%
RPTX - INO
58%
Loosely correlated
N/A
BCYC - INO
55%
Loosely correlated
-0.13%
AXON - INO
53%
Loosely correlated
+2.70%
ARRY - INO
52%
Loosely correlated
+11.93%
ONCO - INO
50%
Loosely correlated
-4.12%
More